Table 1.
Plasma and urine mucosal permeability
| PK Parameter | HEC | N-9 | KY Jelly |
|---|---|---|---|
| AUC0–12, μCi-hrs/mL x 10−6, dose-adjusted | 0.70 (0.30 – 1.30) § | 1.9 (1.59 –9.88) § | 0.58 (0.08 – 2.02) |
| Cmax, μCi/mL x 10−6, dose-adjusted | 0.12 (0.06 – 0.21) § | 0.36 (0.29 – 1.19) § | 0.10 (0.03 – 0.28) |
| Tmax, hours after dosing | 4.00 (3.00 – 8.03) | 9.98 (4.09 – 11.01 ) | 3.00 (2.97 – 8.00) |
| Cumulative urine 99mTc (μCi) as fraction of retained dose x 10−4 (collection interval in hours after dosing) | |||
| 0–2 | 1.97 (0.42 –5.13) | 2.04 (0 –33.30) | 0.46 (0.20 –4.31) |
| 0–4 | 14.30# (3.82 –61.70) | 12.70 (6.28– 134.00) | 2.53# (1.52 –22.50) |
| 0–8 | 32.70# (15.20 –122.00) | 48.90* (30.90 –461.00) | 14.00#* (6.70 –46.80) |
| 0–12 | 66.70# (27.90 –152.00) | 103.00* (98.20 –684.00) | 20.30#* (11.10– 55.90) |
| Residual CVL (fraction of retained dose) | 0.06 (0.02– 0.12) | 0.09 (0.03– 0.19)* | 0.03 (0.01– 0.11)* |
μ Ci: microcurie
AUC, Cmax, and urine are divided by retained dose (μCi), and expressed as a fraction
Data are median (IQR)
Wilcoxon signed-rank tests: P<0.05 for comparisons between
§
HEC and N9;
#
HEC and KY Jelly;
*
N-9 and KY Jelly.